What is Adenocarcinoma of the Fallopian Tube?

Adenocarcinoma of the Fallopian Tube
Histology of an invasive serous-papillary adenocarcinoma of the fallopian tube. Magnification 200 fold (H&E). Paraneoplastic cerebellar degeneration in a patient with a primary fallopian tube adenocarcinoma. A case report and brief review. Gynecologic Oncology Reports. Not Altered. CC.

Adenocarcinoma of the fallopian tube is a type of cancer which develops on the fallopian tubes tissues. 

What is the Pathology of Fallopian Tube Adenocarcinoma?

The pathology of fallopian tube adenocarcinoma is:

-Etiology: The cause of fallopian tube adenocarcinoma is Post menopause, no children, Inherited gene mutations.

-Genes involved: BRCA1 or BRCA2 mutations.

-Pathogenesis: The sequence of events that lead to fallopian tube adenocarcinoma are not fully understood.

-Morphology: The morphology associated with fallopian tube adenocarcinoma shows crowding and a disorganized piling up of cells, frequent mitotic figures, nuclear atypia and necrosis.

-Histology: The histology associated with fallopian tube adenocarcinoma shows malignant glands.

How does Fallopian Tube Adenocarcinoma Present?

Patients with fallopian tube adenocarcinoma typically females present between 50 and 60 years. The symptoms, features, and clinical findings associated with fallopian tube adenocarcinoma include: bleeding from vagina without periods, pain and pressure in lower body, white or pink discharge from vagina, lump and swelling in lower body. 

How is Fallopian Tube Adenocarcinoma Diagnosed?

Fallopian tube adenocarcinoma is diagnosed by: Pelvic Exam test, ultrasound, MRI, CT scan, biopsy, CA125 test.

How is Fallopian Tube Adenocarcinoma Treated?

Fallopian tube adenocarcinoma is treated by: Surgery, chemotherapy, radiotherapy, salpingo-oophorectomy, and hysterectomy.  

What is the Prognosis of Fallopian Tube Adenocarcinoma?

The prognosis of fallopian tube adenocarcinoma is good. The 5-year survival rate for women younger than 65 is 61%, compared with 32% for women age 65 and older.